Thromboprophylaxis after Arthroplasty in Practice of Outpatient Trauma and Orthopedic Physician: is it necessary?


Analysis of the safety and efficacy of the currently marked oral anticoagulants in patients after large joints arthroplastyat outpatient step was presented for the first time in Russian clinical practice. Total number of 5025 patients after total knee and 5216 patients after total hip arthroplasty were examined. All patients were divided into 3 groups depending on prescribed anticoagulant (dabigatran, rivaroxaban or apixaban). Duration of therapy with corresponding drug after hip and knee arthroplasty was initiated after surgery and made up 35 and 45 days, respectively. Deep vein US examination was performed to all patients in 3 and 6 months after discharge. In patients on dabigatran the rate of clinically significant deep vein thrombosis development was lower than in patients on rivaroxaban and apixaban, and made up 5% vs 7.7 and 16%, respectively. Rate of nonfatal pulmonary embolism (PE) was comparable. Relapse of deep vein embolism development was diagnosed only in patients who received rivaroxaban. A suggestion on the expediency of a longer thromboprophylaxis after surgical interventions on large joints was made that would require extensive studies.

Full Text

Restricted Access

About the authors

S. A Firsov

Yaroslavl’ Railway Clinical Hospital, Center of Traumatology and Orthopaedics


R. P Matveev

Northern State Medical University

V. P Shevchenko

Novosibirsk Research Institute of Traumatology and Orthopedics named after Ya.L.Tsivyan

L. S Tumorin

Yaroslavl’ Railway Clinical Hospital, Center of Traumatology and Orthopaedics


  1. Профилактика венозных тромбоэмболических осложнений в травматологии и ортопедии. Российские клинические рекомендации. Травматология и ортопедия России. 2012; 1 (63): 1-24.
  2. Фирсов С.А., Левшин А.Г., Матвеев Р.П. Российский опыт рациональной тромбопрофилактики в травматологии и ортопедии. Вестник травматологии и ортопедии им. Н.Н. Приорова. 2015; 2: 36-42.
  3. Anderson F.A. Jr., Hirsh J., White K., Fitzgerald R.H. Jr. Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996-2001: findings from the Hip and Knee Registry. Chest. 2003; 124: 349S-56S.
  4. Al-Badri A., Spyropoulos A.C. Treatment and long-term management of venous thromboembolism. Clin. Lab. Med. 2014; 34 (3): 519-36.
  5. Ansell J., Hirsh J., Hylek E., Jacobson A., Crowther M., Palareti G. Pharmacology and management of the vitamin K antagonist: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl): 160S-198S.
  6. Cohen A.T., Agnelli G., Anderson F.A., Arcelus J.I., Bergqvist D., Brecht J.G. et al.; VTE Impact Assessment Group in Europe (VITAE). Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb. Haemost. 2007; 98 (4): 756-64.
  7. Bloch B.V., Patel V., Best A.J.Thromboprophylaxis with dabigatran leads to an increased incidence of wound leakage and an increased length of stay after total joint replacement. J. Bone Joint Surg. 2014; 96-B (1): 122-6.
  8. Dietrich M., Zingg P., Egbring M., Kamath A., Dora C. Pre-hospital medications in total hip arthroplasty: risk factors for poor outcomes. Hip Int. 2015; 25(3):215-20.
  9. Hurst K.V., Lee R., Milosevic I., Handa A. Efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase iii trials - key learning points for surgeons. Eur. J. Vasc. Endovasc. Surg. 2015; 50 (1): 126-7.
  10. Pierce T.P., Elmallah R.K., Jauregui J.J., Cherian J.J., Mont M.A. What’s new in venous thromboembolic prophylaxis following total knee and total hip arthroplasty? An update. Surg. Technol. Int. 2015; 26: 234-7.
  11. Eikelboom J.W., Quinlan D.J., Douketis J.D. Extended duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomized trials. Lancet. 2002; 358:9-15.
  12. McCoy C.C., Lawson J.H., Shapiro M.L. Management of anticoagulation agents in trauma patients. Clin. Lab. Med. 2014; 34 (3): 563-74.
  13. Cohen A.T., Tapson V.F., Bergmann J.F., Goldhaber S.Z., Kakkar A.K., Deslandes B., Huang W. et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008;371(9610): 387-94.
  14. Tapson V.F., Hyers T.M., Waldo A.L., Ballard D.J., Becker R.C., Caprini J.A., et al. Antithrombotic therapy practices in US hospitals in an era of practice guidelines. Arch. Intern. Med. 2005; 165: 1458-64.
  15. Wright G.E. Warfarin pharmacogenetics in the era of new oral anticoagulants. Clin. Genet. 2015;88(2):135-6.
  16. Warwick D., Friedman R.J., Agnelli G., Gil-Garay E. Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry. J. Bone Joint Surg. Br. 2007;89 (6):799-807.
  17. NICE Clinical Guideline Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and embolism) in inpatients undergoing surgery. 2007 Available at
  18. Maniscalco P., Caforio M., Imberti D., Porcellini G., Benedetti R.Apixaban versus enoxaparin in elective major orthopaedic surgery: a clinical review. Clin. Appl. Thromb. Haemost. 2015; 21 (2): 115-9.
  19. Metzger A., Nagaraj T. New oral anticoagulants: clinical parameters and uses in practice. Consult. Pharm. 2015;30(6):329-45.
  20. Patel J.P., Couchman L., Chitongo P.B., Flanagan R.J., Arya R. New oral anticoagulants: dosing and monitoring. BMJ. 2015;350:h2655.
  21. Zalpour A., Oo T.H. Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence. Drug Des. Devel. Ther. 2014; 8: 2181-91.
  22. Kalebo P., Anthmyr B.A., Eriksson B.I., Zachrisson B.E. Optimization of ascending phlebography of the leg for screening of deep vein thrombosis in thromboprophylactic trials. ActaRadiol. 1997; 38: 320-6.
  23. Friedman R.J., Caprini J.A., Comp P.C., Davidson B.L., Francis C.W., Ginsberg J. et al.Dabigatranetexilate versus enoxaparin in preventing venous thromboembolism following total knee arthroplasty. J. Thromb. Haemost. 2007; 5 (Suppl. 2): OC051.
  24. Messerschmidt C., Friedman R.J. Clinical experience with novel oral anticoagulants for thromboprophylaxis after elective hip and knee arthroplasty. Arterioscler. Thromb. Vasc. Biol. 2015;35(4):771-8.
  25. Enriquez A., Baranchuk A., Redfearn D., Simpson C., Abdollah H., Michael K.Dabigatran for the prevention and treatment of thromboembolic disorders. Expert Rev. Cardiovasc. Ther. 2015; 13 (5): 529-40.
  26. Vanassche T., Vandenbriele C., Peerlinck K., Verhamme P. Pharmacotherapy with oral Xa inhibitors for venous thromboembolism. Expert Opin. Pharmacother. 2015;16(5):645-58.
  27. Prisco D., Cenci C., Silvestri E., Emmi G., Ciucciarelli L. Pharmacological prevention of venous thromboembolism in orthopaedic surgery. Clin. Cases Miner. Bone Metab. 2014; 11 (3): 192-5.
  28. Botella Gabriel F., Labios Gomez M., Balaguer Martinez J.V., FernándezLlopez A. Prevention of venous thromboembolism: unfractionated heparins and low-molecular weight heparins. Analysis of these 2 options. An. Med. Interna. 2009; 16 (11): 590-600 [In Spanish].
  29. Vaughan Sarrazin M.S., Rose A. Safety of new oral anticoagulants. BMJ. 2015; 350: h1679.
  30. Becattini C., Agnelli G. Aspirin for prevention and treatment of venous thromboembolism. Blood Rev. 2014;28(3):103-8.
  31. Cohn R.M., Della Valle A.G., Cornell C.N. Heterotopic ossification is less after THA in patient who receive aspirin compared to comadin. Bull. NYU Hosp. Jt Dis. 2010; 68 (4): 266-72.
  32. Pavlou G., Salhab M., Murugesan L., Jallad S.,Petsatodis G., West R., Tsiridis E. Risk factors for heterotopic ossification in primary total hip arthroplasty. Hip Int. 2012; 22 (1): 50-5.



Abstract - 25


Article Metrics

Metrics Loading ...


  • There are currently no refbacks.

Copyright (c) 2016 Eco-Vector

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies